Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 279,221,376
  • Shares Outstanding, K 3,101,426
  • Annual Sales, $ 54,073 M
  • Annual Income, $ 7,035 M
  • EBIT $ 12,801 M
  • EBITDA $ 19,489 M
  • 60-Month Beta 0.32
  • Price/Sales 5.21
  • Price/Cash Flow 14.43
  • Price/Book 6.13

Options Overview Details

View History
  • Implied Volatility 22.50% (-0.77%)
  • Historical Volatility 21.00%
  • IV Percentile 27%
  • IV Rank 10.67%
  • IV High 47.30% on 04/08/25
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 14) 2.88 (3.17%)
  • Put/Call Vol Ratio 4.80
  • Today's Volume 2,124
  • Volume Avg (30-Day) 6,518
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 139,004
  • Open Int (30-Day) 133,563
  • Expected Range 88.10 to 93.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.13
  • Number of Estimates 4
  • High Estimate 1.20
  • Low Estimate 1.06
  • Prior Year 1.05
  • Growth Rate Est. (year over year) +7.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.37 +8.52%
on 11/06/25
94.01 -3.77%
on 11/26/25
+9.32 (+11.48%)
since 11/05/25
3-Month
72.89 +24.11%
on 09/25/25
94.01 -3.77%
on 11/26/25
+8.77 (+10.73%)
since 09/05/25
52-Week
61.24 +47.73%
on 04/09/25
94.01 -3.77%
on 11/26/25
+22.94 (+33.97%)
since 12/05/24

Most Recent Stories

More News
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers ...

AZN : 90.44 (+0.46%)
IonQ Wants to Bring Quantum Computing to Medicine. Should You Buy IONQ Stock Here?

With IonQ bringing quantum computing into healthcare, is now the time for investors to start paying attention to this stock?

NVDA : 182.21 (-0.64%)
AZN : 90.44 (+0.46%)
$SPX : 6,876.48 (+0.28%)
IONQ : 52.25 (-4.58%)
AMZN : 229.71 (+0.26%)
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled...

AZN : 90.44 (+0.46%)
Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...

SENS : 6.69 (-0.59%)
AZN : 90.44 (+0.46%)
VTGN : 4.13 (-3.50%)
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the IMFINZI regimen vs. chemotherapy...

AZN : 90.44 (+0.46%)
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

New capacity at AstraZeneca’s Fredrick and Gaithersburg facilities will accelerate production of cancer, rare and chronic disease medicines Fourth...

AZN : 90.44 (+0.46%)
This 1 Company Is the Nvidia of Quantum Computing. Should You Buy Its Stock Now?

IONQ stock is up 20% in the past 52 weeks and remains a top investment as it expands its quantum computing moat, according to investment bank J.P. Morgan.

MSFT : 479.90 (-0.20%)
NVDA : 182.21 (-0.64%)
GOOG : 320.61 (+0.70%)
GOOGL : 319.94 (+0.73%)
AZN : 90.44 (+0.46%)
IONQ : 52.25 (-4.58%)
AMZN : 229.71 (+0.26%)
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN...

AZN : 90.44 (+0.46%)
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

FASENRA also demonstrated a greater improvement in fatigue symptom relief in a single monthly dose compared to placebo

AZN : 90.44 (+0.46%)
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with...

AZN : 90.44 (+0.46%)
ATXI : 0.7800 (-2.50%)
AXSM : 150.52 (+1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 91.78
2nd Resistance Point 91.32
1st Resistance Point 90.68
Last Price 90.44
1st Support Level 89.58
2nd Support Level 89.12
3rd Support Level 88.48

See More

52-Week High 94.01
Last Price 90.44
Fibonacci 61.8% 81.49
Fibonacci 50% 77.63
Fibonacci 38.2% 73.76
52-Week Low 61.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar